USPTO serial 86859702
HEALTH NUCLEUS
Reviewed by CopyMark Law Group
Reg. 5974699Status 710
- Filing date
- Status date
- Registration date
- Feb 4, 2020
- Examiner
- GILBERT, HANNAH B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with HEALTH NUCLEUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anna King
Anna King Banner & Witcoff, Ltd.71 South Wacker Drive, Suite 3600Chicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | scientific research services in the field of genomics and advanced clinical imaging to be used for personalized health; research and development in the field of genome sequencing and genome analysis; providing scientific analysis of aggregated results comprised primarily of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping data, molecular analytics, patient scientific and medical information, genealogical information, health risk assessment, and preparing related information reports therefor; providing scientific analysis of aggregated results comprised primarily of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping data, molecular analytics, patient scientific and medical information, genealogical information, health risk assessment from information obtained through advanced clinical imaging, namely, ultrasound imaging, magnetic resonance imaging (MRI), X-ray, radiography, computed tomography (CT), fluoroscopy, positron emission tomography, mammography, and echocardiogram services, and preparing related information reports therefor; providing online searchable databases in the fields of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping, molecular analytics, patient scientific and medical information, genealogical information, advanced clinical imaging, health risk assessment for scientific research purposes; application service provider (ASP) featuring software for use in data management, data storage, data analysis, report generation, all in the fields of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, and health risk assessment; scientific research in the fields of genomics, genetics, genetic testing, genetic screening, genotyping, phenotyping, molecular analytics, health risk assessment, and genealogical information; scientific research in the fields of genomics, genetics, genetic testing, genetic screening, genotyping, phenotyping, molecular analytics, health risk assessment from information obtained through advanced clinical imaging, namely, ultrasound imaging, magnetic resonance imaging (MRI), X-ray, radiography, computed tomography (CT), fluoroscopy, positron emission tomography, mammography, and echocardiogram services, and genealogical information; medical research; scientific investigations for medical purposes; medical and scientific research in the field of medical imaging; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research in the field of genome sequence analysis and genome sequence reporting for research purposes, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; research and development in the field of genome sequence analysis and genome sequence reporting, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; scientific research for medical purposes in the field of genome sequence analysis and genome sequence reporting, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; genetic testing of humans for scientific research purposes; all for scientific research purposes | SECTION 8 - CANCELLED | Oct 12, 2015 |
| 044 | genetic testing of humans for medical diagnostic purposes; consulting services in the fields of diagnostic medical testing; DNA screening for medical purposes; genetic counseling; medical assistance consultancy provided by doctors and other specialized medical personnel; medical assistance consultancy provided by genomics and genetics experts; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; medical testing of blood, saliva, stool; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a web site featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical information; providing medical information, consultancy and advisory services; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes | SECTION 8 - CANCELLED | Oct 12, 2015 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HLI Nucleus Holdings, LLC
- Other trademarks owned by HLI Nucleus Holdings, LLC
- Other trademarks owned by HLI Nucleus Holdings, LLC
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HEALTH NUCLEUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 14, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 4, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 18, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 18, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 18, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 18, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 18, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 4, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 19, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 19, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 30, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 10, 2019 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Oct 10, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 3, 2019 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Sep 4, 2019 | RBFT | REPLY BRIEF FILED - CHECK TTAB FILES | — |
| Aug 13, 2019 | GNSN | NOTIFICATION OF EXAMINERS STATEMENT E-MAILED | — |
| Aug 13, 2019 | GNES | EXAMINERS STATEMENT E-MAILED | — |
| Aug 13, 2019 | CNES | EXAMINERS STATEMENT - COMPLETED | — |
| Jul 23, 2019 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jul 18, 2019 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 18, 2019 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 18, 2019 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Jun 20, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 12, 2019 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jun 12, 2018 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jun 12, 2018 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Dec 13, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 13, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 13, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 21, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 21, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 21, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 20, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 20, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 19, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2017 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 9, 2017 | ALIE | ASSIGNED TO LIE | — |
| Nov 1, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 19, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 19, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 19, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 19, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 19, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 8, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 7, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 31, 2015 | NWAP | NEW APPLICATION ENTERED | — |